Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910

Conditions

• Exudative Age-related Macular Degeneration

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Aflibercept — DRUG
  Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits

Study Details

The purpose of this research study is to determine if a "Treat and Extend" regimen (increasing the time between visits when the disease is stable and not getting worse) of aflibercept 2.0mg injections inside the eye for treating patients with Wet Age-related Macular Degeneration.

Key Dates

Start date

Oct 31, 2013

Status verified

Oct 2015

Primary completion

Mar 31, 2016

Completion

Jul 31, 2016

Study Design

Enrollment

45 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Aflibercept
  All patients will receive aflibercept 2.0mg intravitreal injection

Primary Outcome Measure

Portion of patients who maintain vision (loss of < or = 5 letters ETDRS BCVA) from baseline to Year 1. [ Time Frame: 1 Year ]

Locations (6)

Find similar trials in Augusta, GA